Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30417113 | 1.00 | HSD11B1 (0.51) | HSD11B1PTPN11TRPV1MAPK13MAPK12 | |
| SCHEMBL13489654 | 1.00 | HSD11B1 (0.51) | HSD11B1PTPN11TRPV1MAPK13MAPK12 | |
| SCHEMBL232057 | 0.83 | TRPV1 (0.47) | HSD11B1TRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL232058 | 0.83 | TRPV1 (0.47) | HSD11B1TRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL3707817 | 0.83 | TRPV1 (0.47) | HSD11B1TRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL30416776 | 0.81 | HSD11B1 (0.51) | HSD11B1TRPV1 | |
| SCHEMBL30416835 | 0.81 | HSD11B1 (0.51) | HSD11B1TRPV1 | |
| SCHEMBL4871696 | 0.81 | CHRNB2 (0.50) | HSD11B1PTPN11TRPV1MALT1 | |
| SCHEMBL7721422 | 0.78 | GHSR (0.45) | MALT1 | |
| SCHEMBL2385053 | 0.78 | MAPK13 (0.43) | PTPN11MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1981848-A2 | 11-BETA HSD1 INHIBITORS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885PTPN11 3147/4885TRPV1 4793/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885PTPN11 2911/4885TRPV1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.